This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: 445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION, Journal of Hepatology, March 2011, Elsevier,
DOI: 10.1016/s0168-8278(11)60447-9.
You can read the full text:
The following have contributed to this page
